Venture capital company Cataterio Capital Management today announced the closure of its $400 million Fund IV, as first reported by Bloomberg. The fund continues its paper on supporting healthcare and biotech companies.
According to Pitchbook, the company was founded in 2020 and has invested more than 100. In particular, Catalio's Fund IV has already supported 16 companies, including diagnostic companies PinkDX and Drug Discovery Company Superluminal Medicines.
The company previously raised $381 million Fund III in 2020 and $100 million Fund II in 2019 on a pitchbook basis.
In particular, the biotech market has not been affected by the venture slump over the past year, followed by higher interest rates and cooler IPO markets. As reported by Bloomberg, the market raised just $12 billion over the past year.